23 Article(s)Download |
||||||
PMID | Title | Pub. Year | #Total Relationships |
|||
1 | 33766630 | Lapatinib alleviates TOCP-induced axonal damage in the spinal cord of mouse. | 2021 May 15 | 3 | ||
2 | 32490320 | Loss of c-Jun N-terminal Kinase 1 and 2 Function in Liver Epithelial Cells Triggers Biliary Hyperproliferation Resembling Cholangiocarcinoma. | 2020 Jun | 2 | ||
3 | 32582968 | Lapatinib‑induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro. | 2020 Sep | 2 | ||
4 | 33176309 | Lapatinib Decreases the Preimplantation Aneuploidy Rate of in vitro Fertilized Mouse Embryos without Affecting Completion of Preimplantation Development. | 2020 | 1 | ||
5 | 30719209 | Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility. | 2019 Jan 4 | 2 | ||
6 | 30125265 | Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo. | 2018 Aug 20 | 6 | ||
7 | 28061785 | Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice. | 2017 Jan 6 | 2 | ||
8 | 26692570 | Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways. | 2016 Mar 1 | 1 | ||
9 | 25375038 | ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. | 2015 Jan | 3 | ||
10 | 25700543 | The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. | 2015 Apr 30 | 1 | ||
11 | 26581390 | Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. | 2015 Nov 18 | 6 | ||
12 | 24279293 | EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship. | 2014 Jan | 2 | ||
13 | 25249538 | Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice. | 2014 Sep 30 | 2 | ||
14 | 23913859 | Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases. | 2013 Nov | 1 | ||
15 | 22011930 | Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. | 2012 Mar | 1 | ||
16 | 22912742 | Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice. | 2012 | 1 | ||
17 | 21685235 | Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. | 2011 Aug | 2 | ||
18 | 20459769 | Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. | 2010 May 11 | 3 | ||
19 | 20735208 | Rational approach to the synthesis, evaluation, and (68)ga labeling of a novel 4-anilinoquinoline epidermal growth factor receptor inhibitor as a new imaging agent that selectively targets the epidermal growth factor receptor tyrosine kinase. | 2010 Aug | 2 | ||
20 | 19141783 | Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. | 2009 Jan 21 | 2 | ||
21 | 19536776 | The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. | 2009 Dec 15 | 3 | ||
22 | 19554571 | Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. | 2009 Oct | 3 | ||
23 | 18664652 | Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. | 2008 Aug 6 | 3 |